Loading...

We've got a brand new version of Simply Wall St! Try it out

Abacus Health Products

CNSX:ABCS
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ABCS
CNSX
CA$157M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Abacus Health Products has significant price volatility in the past 3 months.
ABCS Share Price and Events
7 Day Returns
-8.3%
CNSX:ABCS
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:ABCS
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
ABCS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Abacus Health Products (ABCS) -8.3% 11.3% -25% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on ABCS.
  • No trading data on ABCS.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Abacus Health Products undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Abacus Health Products. This is due to cash flow or dividend data being unavailable. The share price is CA$7.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abacus Health Products's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abacus Health Products's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ABCS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.64
CNSX:ABCS Share Price ** CNSX (2019-09-20) in CAD CA$7.2
CNSX:ABCS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $5.43
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abacus Health Products.

CNSX:ABCS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ABCS Share Price ÷ EPS (both in USD)

= 5.43 ÷ -0.64

-8.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abacus Health Products is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Abacus Health Products is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Abacus Health Products's expected growth come at a high price?
Raw Data
CNSX:ABCS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Abacus Health Products, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Abacus Health Products's assets?
Raw Data
CNSX:ABCS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $1.61
CNSX:ABCS Share Price * CNSX (2019-09-20) in CAD CA$7.2
CNSX:ABCS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $5.43
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:ABCS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ABCS Share Price ÷ Book Value per Share (both in USD)

= 5.43 ÷ 1.61

3.38x

* Primary Listing of Abacus Health Products.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abacus Health Products is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Abacus Health Products's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Abacus Health Products has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Abacus Health Products expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
81.1%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Abacus Health Products expected to grow at an attractive rate?
  • Unable to compare Abacus Health Products's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Abacus Health Products's earnings growth to the Canada market average as no estimate data is available.
  • Abacus Health Products's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:ABCS Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:ABCS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 81.1%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ABCS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ABCS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 114 1
2020-12-31 73 17 2
2019-12-31 19 -18 2
2019-09-22
CNSX:ABCS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 12 -11 -14
2019-03-31 11 -6 -13
2018-12-31 9 1 0
2018-09-30 7 1 1
2017-12-31 3 0 1
2016-12-31 0 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Abacus Health Products is high growth as no earnings estimate data is available.
  • Abacus Health Products's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ABCS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Abacus Health Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ABCS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-09-22
CNSX:ABCS Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.64
2019-03-31 -0.77
2018-12-31 -0.27
2018-09-30
2017-12-31 1.71
2016-12-31 -1.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Abacus Health Products will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Abacus Health Products's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abacus Health Products has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Abacus Health Products performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abacus Health Products's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abacus Health Products does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Abacus Health Products's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Abacus Health Products's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Abacus Health Products's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abacus Health Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ABCS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 12.07 -13.63 13.16 0.56
2019-03-31 10.92 -13.46 8.43 0.48
2018-12-31 8.54 -0.38 3.96 0.12
2018-09-30 6.81 1.46 2.13 0.07
2017-12-31 2.58 0.52 0.76 0.00
2016-12-31 0.08 -0.51 0.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Abacus Health Products has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Abacus Health Products has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Abacus Health Products improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Abacus Health Products's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abacus Health Products has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Abacus Health Products's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abacus Health Products's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abacus Health Products is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abacus Health Products's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abacus Health Products's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Abacus Health Products has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abacus Health Products Company Filings, last reported 2 months ago.

CNSX:ABCS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 34.22 0.00 32.27
2019-03-31 4.99 2.34 12.89
2018-12-31 -0.14 2.20 3.81
2018-09-30 1.40 2.23 4.37
2017-12-31 0.73 0.00 0.35
2016-12-31 0.21 0.00 0.37
  • Abacus Health Products has no debt.
  • Abacus Health Products currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Abacus Health Products has sufficient cash runway for 2.8 years based on current free cash flow.
  • Abacus Health Products has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 92.9% each year.
X
Financial health checks
We assess Abacus Health Products's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abacus Health Products has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Abacus Health Products's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Abacus Health Products dividends.
If you bought CA$2,000 of Abacus Health Products shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Abacus Health Products's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Abacus Health Products's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ABCS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:ABCS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Abacus Health Products has not reported any payouts.
  • Unable to verify if Abacus Health Products's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Abacus Health Products's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Abacus Health Products has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Abacus Health Products's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abacus Health Products afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abacus Health Products has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Abacus Health Products's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Perry Antelman
COMPENSATION $153,217
AGE 54
TENURE AS CEO 0.7 years
CEO Bio

Mr. Perry Antelman serves as Chair of the Board at Abacus Health Products, Inc. He has been Chief Executive Officer of Abacus Health Products, Inc. since January 1, 2019 and also serves as its Director since September 2, 2014. Mr. Antelman has executive business experience, funding, launching, and growing companies in the chemical and medical technology/pharmaceutical sectors. He was the founder and CEO of Tivian Industries, a chemical manufacturer of electro-plating solutions from 1988 to 1999. He was the founder and CEO of Marantech Holdings, a pharmaceutical research company specializing in broad spectrum anti-microbial materials from 1999 to 2004. Since 2004 he has been the CEO of Aidance, a pharmaceutical company specializing in unique dermatological formulations and products sold internationally and into Walgreens and CVS. Mr. Antelman has spent many years in R&D in formulating and product development and has filed more than 30 patents internationally in his extensive career. Mr. Antelman holds a Bachelor of Arts in Computer Science from Yeshiva University, New York.

CEO Compensation
  • Perry's compensation has increased whilst company is loss making.
  • Perry's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Abacus Health Products management team in years:

0.5
Average Tenure
47
Average Age
  • The average tenure for the Abacus Health Products management team is less than 2 years, this suggests a new team.
Management Team

Perry Antelman

TITLE
Chairman & CEO
COMPENSATION
$153K
AGE
54
TENURE
0.7 yrs

Hank Hague

TITLE
CFO & Secretary
COMPENSATION
$215K
AGE
47
TENURE
0.9 yrs

Charlie Hughes

TITLE
Vice President of Operations (Aidance Scientific)

Bharat Madhavan

TITLE
Chief Technology Officer
AGE
37

James Barkat

TITLE
Vice President of Marketing
TENURE
0.4 yrs

Mark Bolling

TITLE
Vice President of Sales
TENURE
0.4 yrs

Jonathan Conforti

TITLE
Vice President of Corporate Development
Board of Directors Tenure

Average tenure and age of the Abacus Health Products board of directors in years:

0.8
Average Tenure
49.5
Average Age
  • The average tenure for the Abacus Health Products board of directors is less than 3 years, this suggests a new board.
Board of Directors

Perry Antelman

TITLE
Chairman & CEO
COMPENSATION
$153K
AGE
54

Hannan Fleiman

TITLE
Director
TENURE
0.2 yrs

Phil Henderson

TITLE
Director
COMPENSATION
$100K
AGE
78
TENURE
0.7 yrs

Jesse Kaplan

TITLE
Director
COMPENSATION
$6K
AGE
36
TENURE
0.9 yrs

Eyal Rosenthal

TITLE
Director
COMPENSATION
$6K
AGE
45
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Abacus Health Products's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abacus Health Products has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Abacus Health Products (CNSX:ABCS) Have A Healthy Balance Sheet?

Check out our latest analysis for Abacus Health Products How Much Debt Does Abacus Health Products Carry? … CNSX:ABCS Historical Debt, July 19th 2019 A Look At Abacus Health Products's Liabilities We can see from the most recent balance sheet that Abacus Health Products had liabilities of US$13.6m falling due within a year, and liabilities of US$2.62m due beyond that. … Abacus Health Products boasts net cash, so it's fair to say it does not have a heavy debt load!

Simply Wall St -

Company Info

Description

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.

Details
Name: Abacus Health Products, Inc.
ABCS
Exchange: CNSX
Founded:
CA$157,397,601
21,860,778
Website: http://abacushp.com
Address: Abacus Health Products, Inc.
10 Wanless Avenue,
Suite 201,
Toronto,
Ontario, M4N 1V6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ABCS Subordinate Voting Shares Canadian National Stock Exchange CA CAD 30. Jan 2019
OTCPK ABAH.F Subordinate Voting Shares Pink Sheets LLC US USD 30. Jan 2019
Number of employees
Current staff
Staff numbers
0
Abacus Health Products employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:47
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/08/29
Last earnings filing: 2019/08/27
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.